文獻(xiàn)標(biāo)題：
1："kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18.
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Chapman AB1, Devuyst O2, Eckardt KU3, Gansevoort RT4, Harris T5, Horie S6, Kasiske BL7, Odland D8, Pei Y9, Perrone RD10, Pirson Y11, Schrier RW12, Torra R13, Torres VE14, Watnick T15, Wheeler DC16; Conference Participants."
2："Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4.
Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.
Eckardt KU1, Alper SL2, Antignac C3,4, Bleyer AJ5, Chauveau D6, Dahan K7, Deltas C8, Hosking A9, Kmoch S10, Rampoldi L11, Wiesener M1, Wolf MT12, Devuyst O13; Kidney Disease: Improving Global Outcomes."
3：alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 1 trials.the lan lancet et oncology.
4：Topical treatment of glaucoma: established and emerging pharmacology
5：Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
[更多]
渝公網(wǎng)安備 50010802001068號(hào)
